FLOT Chemotherapy
Treatment for Stomach Cancer
Typical Dosage: Standard BSA-based regimen (Docetaxel 50mg/m2, Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, 5-FU 2600mg/m2 over 24h, bi-weekly)
Effectiveness
80%
Safety Score
25%
Clinical Trials
46
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Standard BSA-based regimen (Docetaxel 50mg/m2, Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, 5-FU 2600mg/m2 over 24h, bi-weekly)
Time to Effect
2-4 weeks
Treatment Duration
Perioperative (4 cycles pre-op, 4 cycles post-op)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
4(Treat 4 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$25,000
Monitoring:$12,000
Side Effect Mgmt:$18,000
Total Annual:$55,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$130,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$110,000
Cost per Remission
$366,667
Comparison vs ECF/ECX chemotherapy
Cost Difference
+$5,000/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
FLOT Chemotherapy Outcomes
for Stomach Cancer
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+50%
Remission Rate
+15%
Common Side Effects
Neutropenia (Grade 3/4)
+52%
Nausea/Vomiting
+75%
Peripheral neuropathy (Oxaliplatin)
+70%
Diarrhea
+50%
Fatigue
+85%
Alopecia (Docetaxel)
+70%
Sources:
Active Clinical Trials
12 active trials recruiting for FLOT Chemotherapy in Stomach Cancer
Prophylactic Preoperative HIPEC in Advanced Gastric Cancer at High Risk of Peritoneal Recurrence
NCT04597294RECRUITINGPHASE3
600 participants
INTERVENTIONAL
Krakow, Poland
Started: Aug 1, 2021
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
NCT04592913ACTIVE NOT RECRUITINGPHASE3
957 participants
INTERVENTIONAL
Duarte, United States +155 more
Started: Nov 17, 2020
Perioperative FLOT vs Adjuvant XELOX for CA Stomach
NCT05264896RECRUITINGPHASE3
110 participants
INTERVENTIONAL
Hong Kong, Hong Kong
Started: Mar 21, 2022
Preventive Use of PIPAC in Locally Advanced Gastric Cancer.
NCT06784765RECRUITINGNA
160 participants
INTERVENTIONAL
Astana, Kazakhstan
Started: Jan 15, 2025
Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer
NCT06459921NOT YET RECRUITINGPHASE2
200 participants
INTERVENTIONAL
Started: Dec 1, 2024
Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
NCT04384601NOT YET RECRUITINGPHASE3
246 participants
INTERVENTIONAL
Shanghai, China
Started: Sep 1, 2021
A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma
NCT07257575ACTIVE NOT RECRUITINGPHASE2
138 participants
INTERVENTIONAL
Guangzhou, China
Started: Jan 5, 2025
Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer
NCT06028737RECRUITINGPHASE2, PHASE3
150 participants
INTERVENTIONAL
Vilnius, Lithuania +1 more
Started: Mar 25, 2025
A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma
NCT07059299RECRUITINGPHASE1
18 participants
INTERVENTIONAL
Frankfurt, Germany +3 more
Started: Dec 12, 2025
Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness
NCT03421288ACTIVE NOT RECRUITINGPHASE2
677 participants
INTERVENTIONAL
Frankfurt, Germany +1 more
Started: Sep 14, 2018
Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b
NCT06967987NOT YET RECRUITINGPHASE2
49 participants
INTERVENTIONAL
Angers, France +11 more
Started: Dec 30, 2025
Radiomics and Molecular Expression Predictive Model for Esophago-Gastric Junction and Gastric Cancer TRG
NCT04878783ACTIVE NOT RECRUITING
138 participants
OBSERVATIONAL
Padua, Italy +4 more
Started: Dec 20, 2019
Completed Clinical Trials
5 completed trials for FLOT Chemotherapy in Stomach Cancer
Feasibility and Safety of Neoadjuvant Chemotherapy (FLOT ) for Gastric Cancer Patients in China
NCT03646591COMPLETED
10 participants
OBSERVATIONAL
Shanghai, China
Started: Nov 15, 2017
Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
NCT03636893COMPLETEDPHASE2
74 participants
INTERVENTIONAL
Shanghai, China
Started: Aug 24, 2018
Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma
NCT01932580COMPLETEDPHASE2
10 participants
INTERVENTIONAL
Montreal, Canada
Started: Aug 1, 2013
mFLOT Chemotherapy as First-line Treatment in GC
NCT03606928COMPLETEDPHASE1, PHASE2
18 participants
INTERVENTIONAL
Shanghai, China
Started: Jul 1, 2018
Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
NCT02578368COMPLETEDPHASE3
183 participants
INTERVENTIONAL
Frankfurt am Main, Germany
Started: Feb 1, 2016
Showing 20 of 50 total trials